Skip to Main Content

Author Details

Jennifer R Grandis
University of California san francisco
1988
388
83
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
35916666The contemporary management of cancers of the sinonasal tract in adults.CA Cancer J Clin2023
36402737The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Adv Biol Regul2023
35916666The contemporary management of cancers of the sinonasal tract in adults.CA Cancer J Clin2023
37828150Rare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets.Commun Biol2023
37779427To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.Cancer Res2023
37619805New insights into RAS in head and neck cancer.Biochim Biophys Acta Rev Cancer2023
36753744Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.Cancer Res2023
36693157Transcription Factors and Cancer: Approaches to Targeting.Cancer J2023
36857322Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.PLoS One2023
36658129Author Correction: Head and neck squamous cell carcinoma.Nat Rev Dis Primers2023
36595540Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.Clin Cancer Res2023
37619805New insights into RAS in head and neck cancer.Biochim Biophys Acta Rev Cancer2023
37779427To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.Cancer Res2023
37828150Rare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets.Commun Biol2023
36753744Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.Cancer Res2023
36857322Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.PLoS One2023
36693157Transcription Factors and Cancer: Approaches to Targeting.Cancer J2023
36402737The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Adv Biol Regul2023
36595540Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.Clin Cancer Res2023
36658129Author Correction: Head and neck squamous cell carcinoma.Nat Rev Dis Primers2023
34495884Mentoring Relationships and Gender Inequities in Academic Medicine: Findings From a Multi-Institutional Qualitative Study.Acad Med2022
35491622Gender Equity in Science and Medicine: Breaking the Impasse.Cancer Discov2022
36131561Emerging tyrosine kinase inhibitors for head and neck cancer.Expert Opin Emerg Drugs2022
35929989STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.Clin Cancer Res2022
36052496Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
36052495Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
35299655Networking practices and gender inequities in academic medicine: Women's and men's perspectives.EClinicalMedicine2022
34495884Mentoring Relationships and Gender Inequities in Academic Medicine: Findings From a Multi-Institutional Qualitative Study.Acad Med2022
35158773NSAIDs Overcome <i>PIK3CA</i> Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.Cancers (Basel)2022
35491622Gender Equity in Science and Medicine: Breaking the Impasse.Cancer Discov2022
36131561Emerging tyrosine kinase inhibitors for head and neck cancer.Expert Opin Emerg Drugs2022
35929989STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.Clin Cancer Res2022
36052496Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
36052495Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
35158773NSAIDs Overcome <i>PIK3CA</i> Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.Cancers (Basel)2022
35299655Networking practices and gender inequities in academic medicine: Women's and men's perspectives.EClinicalMedicine2022
32883697CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.Mol Cancer Res2021
34067117IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.Cancers (Basel)2021
33888713Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.Nat Commun2021
34045293Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.Clin Cancer Res2021
34261774Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2021
33614939Clinical trials optimizing investigator and self-collection of buccal cells for RNA yield.Laryngoscope Investig Otolaryngol2021
34253636PD-1<sup>+</sup>CXCR5<sup>-</sup>CD4<sup>+</sup> Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma.J Immunother Cancer2021
34346116PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.Head Neck2021
32883697CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.Mol Cancer Res2021
33203730Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.Mol Cancer Ther2021
34680342Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009-2018.Cancers (Basel)2021
34463982Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics.Periodontol 20002021
34779417Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.J Clin Invest2021
34546978Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.JCI Insight2021
  • 1 - 50 of 776

Recommended Authors

Stefano Cavalieri
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Milan
Career Start Year 2016
Number of shared co-authors 1
Morgan Black
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2014
Number of shared co-authors 0
Shuling Ren
Beijing Friendship Hospital, Capital Medical University
Career Start Year 2013
Number of shared co-authors 12
Neil Mundi
Southern Illinois University School of Medicine
Career Start Year 2013
Number of shared co-authors 0
Takahito Fukusumi
Osaka University Graduate School of Medicine
Career Start Year 2012
Number of shared co-authors 11
Shilpa Bhatia
University of Colorado Denver at Anschutz Medical Campus
Career Start Year 2011
Number of shared co-authors 4
Farhoud Faraji
University of California San Diego Health
Career Start Year 2008
Number of shared co-authors 15
Pinaki Bose
Cumming School of Medicine, University of Calgary
Career Start Year 2008
Number of shared co-authors 1
Katharine A Price
Mayo Clinic
Career Start Year 2008
Number of shared co-authors 7
Myung Woul Han
Ulsan University Hospital, University of Ulsan College of Medicine
Career Start Year 2006
Number of shared co-authors 0
Sophia Bornstein
Cornell University
Career Start Year 2005
Number of shared co-authors 2
Mizuo Ando
University of Tokyo
Career Start Year 2005
Number of shared co-authors 12
Antonio L Amelio
University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 8
Sabrina Daniela da Silva
Jewish General Hospital
Career Start Year 2004
Number of shared co-authors 1
Luc G T Morris
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 19
Wei Shi
Research Institute, Princess Margaret Cancer Centre
Career Start Year 2002
Number of shared co-authors 3
Anthony C Nichols
University of Western Ontario
Career Start Year 2001
Number of shared co-authors 9
Sana D Karam
University of Colorado School of Medicine
Career Start Year 2000
Number of shared co-authors 4
Rifat Hasina
University of Chicago Medicine
Career Start Year 1999
Number of shared co-authors 3
Eric J Sherman
Memorial Sloan Kettering Cancer Center
Career Start Year 1999
Number of shared co-authors 9
Richard J Wong
Memorial Sloan Kettering Cancer Center
Career Start Year 1998
Number of shared co-authors 11
Mitchell J Frederick
Baylor College of Medicine
Career Start Year 1995
Number of shared co-authors 19
Zhong Chen
National Institute on Deafness and Other Communication Disorders
Career Start Year 1995
Number of shared co-authors 4
Bhuvanesh Singh
Memorial Sloan Kettering Cancer Center
Career Start Year 1991
Number of shared co-authors 13
Ravindra Uppaluri
Brigham and Women's Hospital
Career Start Year 1988
Number of shared co-authors 13
Jay O Boyle
Memorial Sloan Kettering Cancer Center
Career Start Year 1988
Number of shared co-authors 15
Fei-Fei Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 8
Lisa Licitra
Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan
Career Start Year 1987
Number of shared co-authors 12
Ruud H Brakenhoff
Vrije Universiteit Amsterdam
Career Start Year 1986
Number of shared co-authors 6
Carter Van Waes
National Institute of Deafness and Other Communication Disorders
Career Start Year 1984
Number of shared co-authors 31

Collaborators

Daniel E Johnson
University of California San Francisco
Co-authored papers 67
Ann Marie Egloff
Harvard Medical School, Brigham and Women's Hospital
Co-authored papers 28
Lin Wang
Co-authored papers 28
Neil E Bhola
Zai Lab (US) LLC
Co-authored papers 26
Hua Li
University of California san francisco
Co-authored papers 26
Julie E Bauman
George Washington University
Co-authored papers 26
Raja R Seethala
University of Pittsburgh Medical Center-Presbyterian
Co-authored papers 23
Umamaheswar Duvvuri
University of Pittsburgh School of Medicine
Co-authored papers 23
Yan Zeng
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College
Co-authored papers 20
Simion I Chiosea
University of Pittsburgh
Co-authored papers 18
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 16
Sichuan Xi
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 15
Stephen Y Lai
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Marjorie Romkes
Co-authored papers 11
Rachel A O'Keefe
University of California San Francisco
Co-authored papers 9
Joel L Weissfeld
Co-authored papers 9
Toni M Brand
University of Wisconsin School of Medicine and Public Health
Co-authored papers 9
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Co-authored papers 7
Stefan Hartmann
University Hospital Wurzburg
Co-authored papers 7
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 7
Peter S Hammerman
Novartis Institutes for BioMedical Research
Co-authored papers 6
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 5
Simon C Watkins
Center for Molecular Imaging, University of Pittsburgh School of Medicine
Co-authored papers 5
Patrick K Ha
University of California San Francisco
Co-authored papers 5
Carolyn Kemp
University of Pittsburgh Medical Center, Eye and Ear Institute
Co-authored papers 5
Max V Ranall
University of California San Francisco
Co-authored papers 5
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 5
Ezra E W Cohen
university of california san diego Health System
Co-authored papers 4
Adel K El-Naggar
MD Anderson Cancer Center
Co-authored papers 4
Carl H Snyderman
Co-authored papers 4
Release 1.2